Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of “Buy” by Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been assigned an average rating of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $25.8571.

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Finally, UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th.

Teva Pharmaceutical Industries Stock Up 3.4%

Shares of NYSE:TEVA opened at $27.80 on Thursday. The business’s 50 day moving average is $22.08 and its 200 day moving average is $19.02. The stock has a market cap of $31.89 billion, a P/E ratio of 46.34, a price-to-earnings-growth ratio of 1.44 and a beta of 0.67. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $27.90. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Insider Activity

In other news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares in the company, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cromwell Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the last quarter. Advisors Asset Management Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $41,000. Rothschild Investment LLC lifted its position in Teva Pharmaceutical Industries by 97.0% during the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after acquiring an additional 1,348 shares during the last quarter. JFS Wealth Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 257.1% in the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after acquiring an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC grew its holdings in Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after purchasing an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.